This research also demonstrated that the combination of a BCL2 inhibitor and pan-RAF inhibitor could overcome drug resistance to either compound alone in AML cell lines; furthermore, the combination induced long-term responses in ex vivo AML patient samples that were relapsed/refractory to azacitidine plus venetoclax. The gene discussed is BCL2; the disease is acute myeloid leukemia.